June 11, 2003
Boston Cure Project for MS
Waltham and Cambridge, Mass.
The Boston Cure Project for Multiple Sclerosis (MS) today announced it signed an agreement with Genomics Collaborative, Inc. (“GCI”) to further Boston Cure Project’s multidisciplinary Blood, Tissue and Data Bank pilot to find the causes of MS that lead to a cure. The Tissue and Data Bank is a critical element that proactively increases collaboration amongst MS researchers, in addition to enabling cross-disciplinary breakthroughs not currently possible through individual studies.
Under the terms of the agreement, GCI will help develop the Tissue and Data Bank study protocol, help create an informed consent form for participants, generate and distribute sample kits, prepare and store samples, enter and store sample data (medical and epidemiological), and distribute samples to select researchers¾saving Boston Cure Project over an estimated million dollars. The companies established a pay-as-you go procedure whereby the Boston Cure Project will pay GCI under $200 per subject sample.
“Genomics Collaborative is providing a cost effective way for us to implement our Blood, Tissue and Data Bank pilot, in addition to helping us make an unprecedented number of samples available to MS researchers in a follow-on study,” says Art Mellor, CEO, Boston Cure Project for MS. “After researching several genomic companies, partnering with GCI made perfect sense given its experience effectively managing over 120,000 samples and proximity.”
“Genomics Collaborative is pleased to provide its expertise in tissue and DNA banking to the Boston Cure Project for Multiple Sclerosis. We hope GCI’s contribution to this program will help researchers determine the underlying causes of MS,” says Michael Pellini, M.D., President and Chief Executive Officer of GCI.
The goals of the Blood, Tissue and Data Bank are to: increase scientific collaboration through access to a multidisciplinary resource, free-up time consuming and expensive subject acquisition and sample collection, and make MS a more attractive research area for scientists and companies inventing new technologies. For example, blood and tissue samples from a common set of subjects will be made available to multiple scientists investigating critical questions about the causes of Multiple Sclerosis in different areas. Results from each of these experiments will be collected in the Data bank so they can be analyzed together, enabling cross-disciplinary breakthroughs.
Multiple Sclerosis (MS) is a chronic neurodegenerative disorder of the central nervous system affecting over 400,000 people in the US and 2 million individuals worldwide. MS often results in severe disability including the inability to walk, blindness, cognitive dysfunction, bladder and bowel problems, extreme fatigue and other serious side effects.
About Boston Cure Project for MS
The Boston Cure Project for Multiple Sclerosis (MS) is a national nonprofit organization dedicated to curing MS by determining its causes. Focused primarily on accelerating the pace of MS breakthroughs, the Boston Cure Project seeks to remove obstacles to investigating the causes of MS and encourages collaboration between research organizations and clinicians. It is developing a "Cure Map,” a systematic plan of research into the causes of MS, and is implementing a multi-disciplinary Blood, Tissue and Data Bank to accelerate the search for environmental and genetic factors in MS. For more information about the Boston Cure Project or to make a corporate or individual contribution, call 781/788-0880, or visit www.bostoncure.org.
About Genomics Collaborative
Genomics Collaborative, Inc. (“GCI”), a privately-held biotechnology company, has developed expertise in applying the science of human genetics to drug and diagnostic discovery decisions. The Company’s approach links human genes, proteins, and clinical outcomes through proprietary technology platforms. GCI’s state-of-the-art technology offers a highly efficient method to validate genomics-based drug and diagnostic targets, and has already been validated through partnerships with more than 30 pharmaceutical and biotechnology companies. The Company has prospectively enrolled over 120,000 patients in Global Repository®, and patient recruitment continues in many disease states.
Genomics Collaborative and Genomics Repository are registered trademarks
of Genomics Collaborative, Inc and GCI Access is a trademark of the company.
Boston Cure Project for Multiple Sclerosis is a trademark of Boston Cure
Project for Multiple Sclerosis.
Copyright © 2003, Boston Cure Project for Multiple Sclerosis